Scholar Rock (NASDAQ:SRRK) Sees Unusually-High Trading Volume Following Earnings Beat

Scholar Rock Holding Corporation (NASDAQ:SRRK) saw unusually-strong trading volume on Wednesday after the company announced better than expected quarterly earnings. Approximately 2,499,630 shares were traded during trading, an increase of 148% from the previous session’s volume of 1,008,784 shares.The stock last traded at $44.10 and had previously closed at $44.31.

The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same period in the prior year, the firm posted ($0.64) EPS.

Key Scholar Rock News

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Piper Sandler raised its price target to $58 and initiated/maintained an “overweight” view, implying ~31.5% upside from recent levels — a clear catalyst for buying interest. We are incrementally positive on Scholar Rock (SRRK) Shares; PT Raised at Piper Sandler
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $58 price target, reinforcing analyst optimism and supporting momentum. HC Wainwright Reaffirms Buy; $58 PT
• Positive Sentiment: Q4 2025 results beat consensus — reported EPS/loss was better than expectations (company reported a smaller-than-expected loss), which traders interpret as operational progress ahead of key clinical milestones. Scholar Rock Q4 2025 Press Release / Financial Results
• Neutral Sentiment: Multiple transcripts and call coverage (Seeking Alpha, InsiderMonkey, Yahoo Finance) are available for the Q4 earnings call — useful for investors digging into management commentary on pipelines, cash runway and upcoming catalysts but not a direct immediate catalyst by itself. Q4 2025 Earnings Call Transcript (InsiderMonkey)
• Negative Sentiment: The company acknowledged a correcting press release: while the quarter beat estimates, net loss widened year‑over‑year (reported net loss per share larger than the year‑ago quarter), which could temper enthusiasm until clinical/financial trends become clearer. Correcting and Replacing: Q4 & Full Year 2025 Financial Results

Analysts Set New Price Targets

Several equities research analysts recently commented on SRRK shares. Wolfe Research began coverage on Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target on the stock. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research note on Tuesday. Barclays boosted their target price on Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Finally, Truist Financial increased their price target on shares of Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Scholar Rock has an average rating of “Buy” and a consensus target price of $52.50.

Insider Buying and Selling

In other news, CEO David Hallal sold 57,450 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $2,453,115.00. Following the completion of the transaction, the chief executive officer directly owned 1,541,645 shares in the company, valued at $65,828,241.50. The trade was a 3.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Keith Woods sold 16,746 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $715,054.20. Following the completion of the sale, the chief operating officer owned 583,254 shares in the company, valued at approximately $24,904,945.80. The trade was a 2.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 344,932 shares of company stock worth $15,371,225. 13.30% of the stock is currently owned by company insiders.

Institutional Trading of Scholar Rock

Institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its holdings in shares of Scholar Rock by 609.3% during the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after acquiring an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Scholar Rock by 12.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after purchasing an additional 5,831 shares in the last quarter. Millennium Management LLC lifted its holdings in Scholar Rock by 37.4% during the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after purchasing an additional 54,555 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock valued at $5,460,000 after buying an additional 34,594 shares in the last quarter. Finally, Strs Ohio bought a new stake in Scholar Rock during the first quarter worth about $77,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Trading Up 0.9%

The company’s fifty day moving average price is $45.29 and its two-hundred day moving average price is $39.08. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The company has a market cap of $4.56 billion, a price-to-earnings ratio of -14.19 and a beta of 0.70.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).